Love-hate Triangle: Why Perrigo Rejected Mylan’s Bids

Perrigo executives plan to go it alone based on potential growth in the non-prescription market, acquiring competitors, organic growth and an MS drug. Teva and Israeli investors in Perrigo, will influence Perrigo’s future course.

comments Print
A love-hate triangle that has riveted the pharmaceutical industry in recent months will probably reach a decisive stage in July or August. The three protagonists are Israel-based Teva Pharmaceutical...